In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 6, 2008, Pages 709-718

  Novitzky, Nicolas ^a   Thomas, Valda ^a   du Toit, Cecile ^a   Mcdonald, Andrew ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anti CD52; Graft versus host disease; Reduced intensity conditioning; T cell depletion

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HLA ANTIGEN; MELPHALAN; MESNA; PREDNISONE; STEROID; THALIDOMIDE; VALACICLOVIR; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FEVER; EX VIVO STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFECTION; INTERSTITIAL PNEUMONIA; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OUTCOMES RESEARCH; PORTAL VEIN THROMBOSIS; REDUCED INTENSITY CONDITIONING; REGRESSION ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T CELL DEPLETION;

EID: 43449090375     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.01.007     Document Type: Article

References (42)

1. R.A. Zittoun F. Mandelli R. Willemze Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia New Engl J Med 332 1995 217 223
2. D.J. Weisdorf W.G. Woods M.E. Nesbit Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome Br J Haematol 86 1994 62 69
3. J.M. Goldman R.P. Gale M.M. Horowitz Bone marrow transplantation for chronic myelogenous leukemia in chronic phase Ann Intern Med 108 1988 806 814
4. F. Van Rhee R.M. Szydlo J. Hermans Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 20 1997 553 560
5. A. Valls M. Algara J. Marrugat Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukaemia patients Eur J Cancer 29A 1993 1523 1528
6. H.T. Greinix D. Nachbaur O. Krieger Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry Br J Haematol 117 2002 914 923
7. S. Giralt E. Estey M. Albitar Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukaemia without myeloablative therapy Blood 89 1997 4531 4536
8. S. Slavin A. Nagler E. Naparstek Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease Blood 91 1998 756 763
9. M. Mohty N. Fegueux C. Exbrayat Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy Bone Marrow Transplant 28 2001 335 339
10. S.P. Robinson A.H. Goldstone S. Mackinnon Chemoresistant or aggressive lymphoma following reduced-intensity allogeneic progenitor. An analysis from the Lymphoma Working Group for Blood and Bone Marrow Transplantation Blood 13 2002 4310 4316
11. H. Waldmann G. Hale G. Cividalli Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1) Lancet ii 1984 483 486
12. L. Mohamed Sorror F. Baron R. Storb What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation? Biol of Blood and Marrow Transplant 11 2005 335 344
13. J. Blade D. Samson D. Reece Criteria for evaluating disease response and progression in patients with multiple myeloma treated 15 by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT Br J Haematol 102 1998 1115 1123
14. G. Hale P. Jacobs L. Wood CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells Bone Marrow Transplant 26 2000 69 76
15. N. Novitzky V. Thomas G. Hale Campath-1 Abs ‘in the bag’ for hematological malignancies: the Cape Town experience Cytotherapy 6 2004 172 181
16. M.J. Keating T.L. Smith H. Kantarjian Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome Leukemia 2 1988 403 412
17. R.F. Schlenk A. Benner J. Krauter Individual patient data–based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup J Clin Oncol 22 2004 3741 3750
18. J.C. Byrd R.B. Weiss D.C. Arthur Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461 J Clin Oncol 15 1997 466 475
19. N. Novitzky V. Thomas G. Hale Ex vivo depletion of T-cells from BM grafts with CAMPATH 1G in acute leukemia: Graft vs Host disease and Graft vs. Leukemia effect Transplantation 67 1999 620 626
20. D.R. Sutherland L. Anderson M. Keeney The ISHAGE guidelines for CD34+ cell determination by flow cytometry J Hematotherapy 5 1996 213 226
21. H. Glucksberg R. Storb A. Fefer Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors Transplantation 18 1974 295
22. N. Novitzky R. Rubinstein J.M. Hallett Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy Transplantation 69 2000 1358 1363
23. P.D. Greenberg P.S. Stewart K.M. Sullivan Bone marrow transplantation in patients aged 45 years and older Blood 67 1986 770 776
24. M. Gomez-Nunez R. Martino M.D. Caballero Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning: results from the Spanish multicenter prospective trial Bone Marrow Transplant 33 2004 477 482
25. H.G. Sayer M. Kroger J. Beyer Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: 16 disease status by marrow blasts is the strongest prognostic factor Bone Marrow Transplant 31 12 2003 1089 1095
26. J.E. Levine J.P. Uberti L. Ayash Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy Marrow Transplant 9 3 2003 189 197
27. R. Martino S. Iacobelli R. Brand Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 2006 836 846
28. E.P. Alyea H.T. Kim V. Ho Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome Biol Blood and Marrow Transplant 12 2006 1047 1055
29. M. de Lima A. Anagnostopoulos M. Munsell Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 3 2004 865 872
30. F. Aversa A. Terenzi A. Carotti Martelli improved outcome with T cell–depleted bone marrow transplantation for acute leukemia J Clin Oncol 17 1999 1545 1550
31. C. Canals R. Martino A. Sureda Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection Exp Hematol 31 2003 1039 1043
32. A. Bacigalupo T. Lamparelli F. Gualandi Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants Biol Blood Marrow Transplant 8 2002 656 661
33. G. Hale M.-Q. Xia H.P. Tighe The CAMPATH-1 antigen (Cdw 52) Tissue Antigens 35 1990 118 127
34. A.H. Elmaagacli R. Peceny N. Steckel Outcome of transplantation of highly purified 17 peripheral blood CD34 cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia Blood 101 2003 446 453
35. R.J. Soiffer E. Weller E.P. Alyea CD61 donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors J Clin Oncol 19 2001 1152 1159
36. R.E. Champlin J.R. Passweg M.J. Zhang T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities Blood 95 2000 3996 4003
37. S. Chakrabarti D. MacDonald G. Hale T-cell depletion with Campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival Br J Haematol 121 2003 109 118
38. J.A. Perez-Simon P.D. Kottaridis R. Martino Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders increased after DLI Blood 100 2002 3121 3127
39. S. Chakrabarti S. Mackinnon R. Chopra High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath- 1H in delaying immune reconstitution Blood 99 2002 4357 4363
40. E.C. Morris P. Rebello K.J. Thomson Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications Blood 102 2003 404 406
41. G. Gahrton S. Tura P. Ljungman Allogeneic bone marrow transplantation in multiple myeloma N Engl J Med 325 1991 1267 1273
42. G. Gahrton H. Svensson M. Cavo Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres Br J Haematol 113 2001 209 216